RecruitingPhase 2NCT06670352

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Intervention
Placebo(drug)
Enrollment
80 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06670352 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials